BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per a report published by Fact.MR, the global wireless handheld ultrasound devices market is poised to total US$ 666 million by the end of 2021.

Galderma, the world’s largest independent dermatology company, marks the 25th anniversary of RESTYLANE®.

Hemogenyx Pharmaceuticals plc, the StandardListed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2021.

AlzeCure Pharma AB announced that the company is participating at the Vator Healthcare Innovation Summit at Epicenter Stockholm on October 7 at 10:20 CEST, where CEO Martin Jönsson will present the company’s latest developments.

All three tirzepatide doses led to more time in tight target range, improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in adults with type 2 diabetes in a continuous glucose monitoring sub-study1 of Eli Lilly and Company’s phase 3 SURPASS-3 clinical trial.

Isarna Therapeutics announced the appointment of Claus Schalper as Chief Executive Officer. Mr. Schalper joins Isarna with over 20 years of experience as an executive and serial entrepreneur in the life science and biotech industries.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced enrollment of the first patient in its phase 2 CALLIPER trial of lead asset IMU-838, the company’s selective oral DHODH inhibitor, in patients with progressive multiple sclerosis.

Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Barbara Regonini to the newly created post of Financial Director.

Nurix Therapeutics, Inc. today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021.

AngioDynamics, Inc. today announced financial results for the first quarter of fiscal year 2022, which ended August 31, 2021.